Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer

Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer

Abstract In this work, we report on a clinically significant response of meningeal carcinomatosis to repotrectinib in a woman with a heavily pretreated ROS1-rearranged non-small cell lung cancer (NSCLC) that harbored the concomitant solvent front G2032R mutation. Meningeal carcinomatosis has a highe...

Full description

Bibliographic Details
Main Authors: Giulio Metro, Eleonora Gariazzo, Silvia Costabile, Sara Baglivo, Fausto Roila, Francesca Colamartini, Barbara Palumbo, Pietro Chiarini, Stefania Gori, Antonio Conti, Luca Marcomigni, Guido Bellezza, Gianluigi Lunardi
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-11-01
Series:Oncology and Therapy
Subjects:
NSCLC
Meningeal carcinomatosis
ROS1-TKIs
Repotrectinib
G2032R mutation
Online Access:https://doi.org/10.1007/s40487-023-00251-6

Internet

https://doi.org/10.1007/s40487-023-00251-6

Similar Items